Kidney Cancer: Drugs
(asked on 24th June 2016) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when he plans to make a decision on the drug Nivolumab becoming available under the Early Access to Medicines Scheme to treat patients with renal cell carcinoma.
This question was answered on 30th June 2016
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a positive scientific opinion concerning the use of nivolumab for renal cell carcinoma under the Early Access to Medicines Scheme on 11 February 2016. This scientific opinion has now lapsed as nivolumab has received its marketing authorisation for use in for renal cell carcinoma from the European Commission.